Paul Vigano Sells 1 Million Shares of AVAH

On June 24, 2026, Paul Vigano sold 1 million shares of AVAH at a price of $8 each, amounting to a total transaction value of $8 million. This insider transaction was not planned under a Rule 10b5-1 trading plan.

Insider Buying and Selling at Aveanna Healthcare Holdings Inc.

Several insiders executed sales of AVAH shares on June 24, 2026. J.H. Whitney Equity Partners VII, LLC sold 919,389 shares at $8 each, while Robert Williams Jr. also sold 1 million shares at the same price. Earlier in the month, on June 3, Vigano and Williams each sold 7 million shares at $6.24, and J.H. Whitney Equity Partners VII, LLC sold 5,842,240 shares at the same price.

Other Institutional Activity in AVAH

Bain Capital Investors LLC maintained its position in AVAH with 81,600,880 shares valued at about $525.5 million. J.H. Whitney Equity Partners VII, LLC also held steady with 36,242,631 shares worth approximately $233.4 million. Nut Tree Capital Management, LP increased its holdings by 550,000 shares to a total of 12,922,649 shares, valued at $83.2 million, marking a 4.4% increase. BlackRock, Inc. trimmed its position by 656,532 shares, leaving it with 5,500,912 shares valued at $35.4 million, a 10.7% decrease. Summit Partners L P reduced its holdings by 2.1 million shares to 5,451,422 shares, worth $35.1 million, a 27.8% decrease. Meanwhile, Vanguard Capital Management LLC opened a new position with 3,974,819 shares valued at $25.6 million.

Aveanna Healthcare Holdings Inc. Stock Down 36.3%

Shares of AVAH traded near $8.48 on Friday. The stock has seen a 52-week low and high, reflecting its market performance over the past year. Institutional activity and insider transactions can often impact the stock's movement.

Analysts Set New Price Targets

Barclays maintained a 'buy' rating on AVAH with a price target of $9 on May 18, 2026. Stephens & Co. upgraded the stock to a 'buy' with a target of $11 on May 15, 2026. RBC Capital maintained a 'hold' rating with a $10 target on the same date. The consensus among analysts suggests a positive outlook, with an average target price reflecting potential upside.

Bottom Line

Paul Vigano's sale of 1 million shares of AVAH highlights ongoing insider activity, which investors often monitor for potential signals about a company's prospects. While insider sales can raise questions, they are not uncommon and may not necessarily indicate negative sentiment. Analysts continue to view AVAH positively, with several maintaining 'buy' ratings and setting price targets above current levels.